Polycystic ovary syndrome (PCOS) is the most common hormonal disorder in women of reproductive age, affecting approximately 8–13% of women worldwide. It is characterized by a combination of irregular periods, elevated androgens (male hormones), and ovaries that contain many small antral follicles. PCOS is one of the leading causes of infertility and carries significant long-term implications for metabolic, cardiovascular, and endometrial health.
PCOS is both a reproductive and a systemic metabolic condition whose consequences extend well beyond the ovaries. The chronic anovulation and unopposed estrogen exposure that characterize PCOS directly increase the risk of endometrial cancer — the uterine lining proliferates without the protective monthly progesterone withdrawal of a normal cycle. The hormonal imbalance of PCOS also predisposes to ovarian cysts, and on imaging the polycystic ovary must be distinguished from a true hemorrhagic ovarian cyst or endometrioma. When androgen levels are markedly elevated, androgen-secreting ovarian tumors must be excluded — MRI of the ovaries and adrenal glands is the appropriate study in this scenario.
Causes
Hormonal and metabolic dysfunction.
PCOS results from a complex, incompletely understood interplay of hormonal imbalances and metabolic dysregulation. Insulin resistance is the central metabolic driver in the majority of affected women — when peripheral tissues respond poorly to insulin, the pancreas compensates with hyperinsulinemia, and chronically elevated insulin levels stimulate the ovarian theca cells to produce excess androgens (primarily testosterone and androstenedione). These excess androgens disrupt the normal selection and maturation of the dominant follicle, preventing ovulation. Instead of one follicle maturing and releasing an egg, multiple small follicles (2–9 mm in diameter) accumulate in the ovary without reaching maturity — the sonographic "string of pearls" appearance and the source of the condition's name. The elevated luteinizing hormone (LH) to follicle-stimulating hormone (FSH) ratio — typically greater than 2:1 in PCOS — further promotes androgen production while suppressing normal follicle maturation and ovulation.
Other contributing factors.
Genetics play a substantial and well-established role — PCOS has a heritability estimated at 70%, and first-degree female relatives of affected women have a 20–40% risk of PCOS themselves. The specific genes involved likely include those regulating insulin signaling, androgen biosynthesis, and gonadotropin secretion. Obesity — while not required for diagnosis — dramatically worsens insulin resistance and hyperandrogenism, amplifying all features of the syndrome, and is present in approximately 50–80% of women with PCOS in Western countries. However, the lean PCOS phenotype is well-recognized and should not be dismissed because the patient is not obese. PCOS typically becomes clinically apparent in the late teens or early twenties, often at menarche, though the hormonal predisposition is likely present from fetal life.
Symptoms
PCOS presents with a wide and heterogeneous spectrum of symptoms driven by three core pathophysiologic mechanisms: ovulatory dysfunction, androgen excess, and metabolic dysregulation. Menstrual irregularity — ranging from infrequent periods (oligomenorrhea, defined as fewer than 8 cycles per year) to complete absence of periods (amenorrhea) — is the most common presenting symptom and reflects chronic anovulation. Infertility affects approximately 70–80% of women with PCOS who are actively trying to conceive, making it one of the most common treatable causes of female infertility. Androgen-driven symptoms include hirsutism (excess terminal hair growth in a male distribution — upper lip, chin, chest, abdomen, inner thighs), acne, oily skin, and scalp hair thinning (female-pattern alopecia). Metabolic symptoms include weight gain concentrated in the abdomen, fatigue, difficulty losing weight despite dietary effort, and acanthosis nigricans — dark, velvety skin thickening at the neck, axillae, and groin that is a visible marker of insulin resistance. Long-term untreated PCOS significantly elevates the risk of type 2 diabetes, metabolic syndrome, cardiovascular disease, non-alcoholic fatty liver disease, obstructive sleep apnea, and endometrial cancer from chronic anovulation.
Diagnosis
PCOS is a clinical and biochemical diagnosis based on the Rotterdam criteria (2003), which require the presence of at least two of the following three features: oligo- or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on imaging — after exclusion of other disorders that mimic PCOS (congenital adrenal hyperplasia, thyroid disease, hyperprolactinemia, and androgen-secreting tumors). Laboratory evaluation includes total and free testosterone, DHEAS, LH, FSH, AMH (anti-Müllerian hormone — often significantly elevated in PCOS and a sensitive marker of follicle pool size), thyroid function, prolactin, and fasting glucose and insulin. Pelvic ultrasound is the standard imaging study and demonstrates the characteristic polycystic ovarian morphology: ovaries containing 20 or more follicles of 2–9 mm per ovary, and/or ovarian volume greater than 10 mL.
An MRI of the pelvis is not required for routine PCOS diagnosis but is valuable in several specific clinical scenarios: when transvaginal ultrasound is technically suboptimal or declined; when androgen levels are markedly elevated (total testosterone above 150–200 ng/dL) suggesting an androgen-secreting ovarian or adrenal tumor rather than PCOS; when evaluating for concurrent pelvic pathology such as an endometrioma, fibroid, or adenomyosis that may be contributing to abnormal bleeding or pelvic pain; or when ruling out other structural causes of anovulation. On MRI, polycystic ovaries appear enlarged with a thickened stroma and multiple small T2-hyperintense peripheral follicles arranged in the characteristic necklace pattern — MRI provides superior soft tissue resolution for follicle counting and stromal assessment compared to ultrasound in challenging anatomic situations.
Classification (Rotterdam phenotypes)
PCOS encompasses four recognized phenotypic patterns based on which of the three Rotterdam criteria are present. Different phenotypes carry different metabolic risk profiles.
- Phenotype A (Classic PCOS): All three features — oligo/anovulation, hyperandrogenism, and polycystic ovarian morphology. The most common and metabolically severe phenotype, with the highest risk of insulin resistance, metabolic syndrome, and cardiovascular disease.
- Phenotype B: Oligo/anovulation and hyperandrogenism without polycystic ovarian morphology on imaging. Carries similar metabolic risk to Phenotype A despite normal-appearing ovaries.
- Phenotype C (Ovulatory PCOS): Hyperandrogenism and polycystic ovarian morphology with regular ovulation. The mildest metabolic phenotype — fertility is typically preserved.
- Phenotype D (Non-hyperandrogenic PCOS): Oligo/anovulation and polycystic ovarian morphology without androgen excess. The most disputed phenotype — whether this truly represents PCOS or a distinct condition remains debated. Lowest metabolic risk of the four phenotypes.
Treatments
Treatment is individualized to the patient's primary concerns — menstrual regulation, fertility, metabolic risk reduction, or androgen-driven cosmetic symptoms. No single treatment addresses all aspects of PCOS simultaneously.
Lifestyle modification: Weight loss through caloric restriction and regular aerobic exercise is the most effective intervention for overweight women with PCOS — even a 5–10% reduction in body weight can restore regular ovulation, reduce androgen levels, improve insulin sensitivity, and lower long-term cardiovascular and diabetic risk. For lean women with PCOS, exercise and dietary optimization remain beneficial even without weight loss targets, by reducing insulin levels and improving metabolic parameters independent of weight.
Medications for menstrual regulation and androgen symptoms.
Combined oral contraceptives (COCs) are the cornerstone pharmacologic treatment for women who are not actively trying to conceive. They suppress LH-driven ovarian androgen production, deliver monthly progestin withdrawal to protect the endometrium, and improve acne and hirsutism. Anti-androgen medications — spironolactone (100–200 mg/day) most commonly — directly block androgen receptor activity and reduce hirsutism and acne when COCs alone are insufficient; they must be combined with contraception due to teratogenic risk. Regular endometrial protection through withdrawal bleeding is critically important to reduce the risk of endometrial hyperplasia and cancer from unopposed estrogen in anovulatory cycles.
Medications for insulin resistance.
Metformin — a biguanide that reduces hepatic glucose production and improves peripheral insulin sensitivity — is a well-established adjunct treatment for PCOS, particularly in women with overt insulin resistance, glucose intolerance, or type 2 diabetes. It lowers circulating insulin, reduces ovarian androgen production, and can restore ovulation in some women. It is frequently used in combination with lifestyle modification. Newer GLP-1 receptor agonists (semaglutide, liraglutide) are emerging as effective options for weight reduction and metabolic improvement in PCOS, though their specific role in PCOS management is still being defined by ongoing trials.
Fertility treatment.
For women actively trying to conceive, letrozole (an aromatase inhibitor) is now established as the first-line ovulation induction agent in PCOS, having demonstrated higher live birth rates than clomiphene citrate in large randomized trials. Clomiphene remains an alternative. For women who fail oral ovulation induction, laparoscopic ovarian drilling — a surgical procedure that destroys a portion of ovarian androgen-producing theca tissue — can restore spontaneous ovulation in some patients. Gonadotropin injections and in vitro fertilization (IVF) are offered when oral induction has failed, with PCOS patients requiring careful monitoring to avoid ovarian hyperstimulation syndrome (OHSS).
Long-term health monitoring.
Given the elevated lifetime risks associated with PCOS, ongoing surveillance is an important component of care: fasting glucose and HbA1c every 1–3 years (or annually in high-risk patients), lipid panel, blood pressure monitoring, and assessment of menstrual pattern regularity to ensure adequate endometrial protection throughout the reproductive and perimenopausal years.
Get an MRI to Confirm Your Diagnosis
Before surgical planning or starting treatment, a clear MRI diagnosis ensures the right path forward. First Look MRI offers self-pay Pelvis MRI scans — no doctor's order or insurance required — at our locations in Georgia, Texas, and Colorado.